Evidence map›Paper›PMID 26191406›Full record

ArticleBiomaterials science2015

Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric Nanomedicines.

Te-Wei Chu, Jindřich Kopeček

Abstract read
In one paragraph

Article in Biomaterials science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Multi-targeted immunotherapeutics to treat B cell malignancies.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Polymer nanomedicines.Advanced drug delivery reviews · 2020
    Review
  14. Article
  15. Article
  16. Article
  17. Drug-free macromolecular therapeutics: Impact of structure on induction of apoptosis in Raji B cells.Journal of controlled release : official journal of the Controlled Release Society · 2017
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Te-Wei ChuDepartment of Pharmaceutics and Pharmaceutical Chemistry/Center for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT 84112, USA.
Jindřich KopečekDepartment of Pharmaceutics and Pharmaceutical Chemistry/Center for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT 84112, USA ; Department of Bioengineering, University of Utah, Salt Lake City, UT 84112, USA.

Funding

Drug-Free Macromolecular TherapeuticsR01GM095606 · NIGMS · UNIVERSITY OF UTAH · PI KOPECEK, JINDRICH H. · 2011 to 2018
$2.3M
NIGMS NIH HHS GM95606NIGMS NIH HHS R01 GM095606
6 · The paper itself

Abstract

This review highlights a unique research area in polymer-based nanomedicine designs. Drug-free macromolecular therapeutics induce apoptosis of malignant cells by the crosslinking of surface non-internalizing receptors. The receptor crosslinking is mediated by the biorecognition of high-fidelity natural binding motifs (such as antiparallel coiled-coil peptides or complementary oligonucleotides) that are grafted to the side chains of polymers or attached to targeting moieties against cell receptors. This approach features the absence of low-molecular-weight cytotoxic compounds. Here, we summarize the rationales, different designs, and advantages of drug-free macromolecular therapeutics. Recent developments of novel therapeutic systems for B-cell lymphomas are discussed, as well as relevant approaches for other diseases. We conclude by pointing out various potential future directions in this exciting new field.

Indexed as

ApoptosisDrug CarriersDrug Delivery SystemsDrug DesignHumansLymphoma, B-CellMacromolecular SubstancesNanomedicineNeoplasmsPolymersDrug CarriersMacromolecular SubstancesPolymers

Identifiers

PMID26191406
PMCPMC4505834

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.